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Abstract
Objective—To determine the plasma triglyceride (TG) and unbound free fatty acid (FFAu) levels
in infants treated with increasing dosages of soybean lipid, intralipid (IL), infusion.
Study design—TG and FFAu levels were measured in 78 preterm infants (BW 500–2000 g; GA
23–34 weeks) using the fluorescent probe ADIFAB2 and enzymatic method.
Results—The infants’ BW was 1266.2 ± 440.7 g and GA 28.8 ± 3.1 weeks. TG levels were 77.4
± 50 mg/dL, 140.2 ± 188 mg/dL (p < .04 compared to levels during low dose IL infusion) and
135.6 ± 118 mg/dL (p < .004), respectively during increased IL rates. FFAu levels were 17.7 ± 13
nM, 47.3 ± 102.8 nM (p = .07) and 98 ± 234 nM (p = .03). TG levels correlated with IL dose, the
rate of IL administration, and FFAu levels. TG and FFAu levels were higher in infants below 28
weeks’ gestation
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Conclusions—Increasing dosage of IL is associated with increasing levels of TG and FFAu,
especially in infants below 29 weeks of gestation. The increased level of FFAu suggests inefficient
cellular utilization.
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Introduction
Intravenous fat emulsion is an important part of parenteral nutrition in preterm infants [1,2].
The commonly used soybean lipid infusion is intralipid (IL), an emulsion of soy bean oil,
egg phospholipids and glycerin, usually administered in a 20% concentration [3]. The
metabolism of IL involves hydrolysis of the triacylglycerols by endothelial lipoprotein
lipases in the presence of cofactor apolipoprotein C-II, releasing free fatty acids (FFA) and
glycerides [1]. The FFA are used in liver, heart or skeletal muscles as metabolic fuel or enter
into adipose tissue to be re-esterified to triglycerides.
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The tolerance of lipid infusions is based on the ability to hydrolyze serum triglycerides (TG)
into FFA. Elevations of TG are used as markers for lipid intolerance and predictors of the
probability of complications involved with the administration of intralipid [4]. Intralipid
infusion carries many risks including potential exacerbation of chronic lung disease,
displacement of bilirubin from albumin, exacerbation of sepsis, thrombocytopenia and
central nervous system injury [1]. Furthermore, significant elevations of plasma FFA levels
could result from the lipase-mediated hydrolysis of triglycerides [2]. Lipoprotein lipase
activity is increased by advancing gestational and postnatal age, and inhibited by stress and
malnutrition, as seen in the small for gestational age infant [5]. FFA levels reflect the ability
of the liver to clear and transport them to various organs for their biologic functions. While
most of the circulating FFA binds to albumin, a small fraction dissociates from albumin as
the free, unbound molecule (FFAu) [6,7]. Elevation of the latter suggests poor transport of
FFA to various organ with less nutritional values. To improve our understanding of the
metabolic process during IL infusion, we examined TG and FFAu levels in preterm infants
treated with increasing dosage of IL. We hypothesized that increased dose of IL will result in
increased TG and FFAu levels, the latter a result of inefficient cellular utilization.
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Materials and methods
Patients
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We measured triglyceride (TG) levels in 78 preterm infants weighing under 2000 g at birth
as part of a study to assess the effect of intralipid administration on bilirubin metabolism [8].
Unbound fatty acid (FFAu) levels were also measured using the fluorescent probe ADIFAB2
in the plasma samples. Recruitment was carried out in the Neonatal Intensive Care Unit
(NICU) at Rutgers, Robert Wood Johnson Medical School (RWJMS) and the study was
approved by the IRBs of Rutgers and the Torrey Pines Institute for Molecular Studies.
Parental informed consent was obtained and each infant was treated with IL infusion from 1
to 3 g/kg/d in 1-g/kg/d steps increase during the first week of life. Because the laboratory
policy is to store all infants blood samples for 7 days it was possible to obtain research
samples earlier than the age of the infant at consent.
Study design
Plasma TG levels were obtained by the clinicians as part of infant parenteral nutrition
management with 20% IL administration. The age of IL initiation was 24.0 ± 9.2 hours
(range 8–55 hours). The number and timing of TG samples and the decision to withhold,
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reduce or terminate the lipid infusion due to high TG levels were determined by the clinical
staff and resulted in a range of the number of triglyceride samples and the age at collection
among the infants. TG level data that was accompanied by information on the dose of
intralipid and the FFAu levels were utilized for the analysis. The clinical team was unaware
of FFAu measurement results.
Blood sampling
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Plasma samples for TG levels were obtained rarely before IL infusion (IL0) and randomly
during infusions of 1, 2 and 3 g/kg/day (IL1, IL2, IL3). Samples for FFAu levels were
obtained from residual samples drawn for clinical indications during those IL dosing
windows. These samples were collected immediately after completion of the requested
clinical test, processed and frozen. The deidentified samples were stored at —70 °C and then
shipped to Fluoresprobe Sciences for determination of FFAu. Of note, serum albumin levels
were not available for analysis.
TG measurements
An automated enzymatic method was used for the measurement of plasma TG (Roche
Diagnostics, Florham Park, NY), which included primary hydrolysis of the triglycerides and
phosphorylation of the resulting glycerol followed by colorimetric detection of the
enzymatic products.
FFAu measurements
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FFAu was measured in the plasma sample using a fluorescently labeled mutant of a fatty
acid binding protein [9,10]. FFAu concentrations were determined using the ADIFAB2
probe [10]. Fluorescence was assessed at two emission wavelengths: 457 and 550 nm for the
FFAu probe (excitation = 375 nm). The ratio of fluorescence at the two wavelengths,
together with probe characteristics, yielded the FFAu concentrations. Fluorescence was
measured at 22 °C using a handheld ratio fluorometer in which plasma sample volumes were
4 mL for FFAu measurements and after dilution the total volume was 200 µL so that FFAu
was measured at 50 fold dilution of the plasma sample [9,10].
Statistical analysis
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The outcome variables (shown as mean ± standard deviation) were treated as continuous,
normally distributed and examined with the Student t test and chi-square test to document
TG level differences at different dosages of IL. IL infusion rate was calculated using the IL
dose and infant weight at time of IL administration. The changes in TG levels as a function
of increasing dose of IL were analyzed by repeated measures analysis. Correlation analysis
was performed to evaluate the relationship between TG levels and IL administration rate and
FFAu concentrations. The analyses were performed with Statistica (StatSoft, Palo Alto, CA);
p < .05 was considered significant.
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Results
One hundred thirty-three paired TG and FFAu levels were obtained during the first 10 days
of life in 78 preterm infants with a birth weight of 1266.2 ± 440.7 g and gestational age 28.8
± 3.1 weeks.
Because the number of samples is small for pre-IL infusion, we compared the changes in TG
and FFAu when the IL dose was increased from 1 g/kg/24 hours to 2 and 3 g/kg/24 hours.
As shown in Table 1, TG increased significantly when the IL dose was increased from 1 to 2
and 3 g/kg/24 hours (p values, .04 and .004), respectively. The FFAu also increased when IL
dose was increased from 1 to 2 and 3 g/kg/24 hours, (p values, .07 and .03, respectively).
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TG levels significantly correlated with IL dose (r = .19), with the rate of IL administration (r
= .24), as shown in Figure 1, and with FFAu levels (r = .29), as shown in Figure 2.
Interestingly, FFAu levels did not correlate with the rate of IL infusion.
Table 2 shows that TG levels were higher in infants below 29 weeks’ gestation, with
significant differences noted at 1 g/kg/24 hours (p = .018) and 2 g/kg/24 hours (p = .009)
infusions. FFAu levels were higher in these infants (p = .07) during infusions of 2 and 3
g/kg/24 hours. Among the 25 infants below 29 weeks of gestation (GA-gestational age (BW)
808.2 ± 224.9 g, GA 25.4 ± 1.7 weeks), 7 (28.0%) had at least one TG level >250 mg/dL,
compared to 3 (5.7%) of the 53 ≤ 29 weeks (BW 1532.6 ± 289.2 g, GA 30.8 ± 1.7 weeks) (p
= .01).
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Preterm infants often cannot be fed adequately via the enteral route and require parenteral
nutrition to provide the various nutrients and energy. Intravenous lipid emulsions, important
constituents of parenteral nutrition, provide increased caloric intake and long-chain
polyunsaturated fatty acids necessary for normal neural development and function. These
lipids are metabolized by lipoprotein lipases releasing triglycerides and free fatty acids
which can be used as metabolic fuel in the liver, heart and skeletal muscles or which can
enter fat cells to be either re-esterified to triglycerides or stored [11]. Most of the FFA in
serum is bound to albumin but a small portion is unbound [12]. The unbound free fatty acid
(FFAu) level in adults is 1.5 ± 0.9 nM [13] and in term infants 13.9 ± 3 nM [14].
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The inability to effectively clear triglycerides leads to hypertriglyceridemia, which has been
associated with a number of adverse effects [15], including complication of disorders of
preterm infants. While the inadvertent overdose of lipid emulsions has resulted in severe
hypertriglyceridemia causing severe clinical symptoms, the level of safety has been
suggested to be below 250 mg/dL [16], although different TG concentration norms have also
been recommended [1]. These ranges are 100–150, < 200, and <250 mg/dL [1]. Several
reviews have examined the metabolism of triglycerides in intravenous fat infusions [2,17].
Morris noted peak TG level was 116.8 ± 60.9 mg/dL, which declined rapidly after the
cessation of IL. TG levels reflect a combination of endogenous and infused TG, controlled
by the variability of IL metabolism by individual infants. Thus, that measurement of lipid
fractions is only useful if the endogenous and infused TG can be separated, measures usually
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not available to the clinician who has to rely on total TG levels to assess the risk of the lipid
infusion [18].
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The study suffers from the random collection of samples due to the discretion of the
clinicians, but, in spite of this limitation, we are confident in the results which show that
increasing dosage of IL is associated with increasing TG and FFAu levels. We have
demonstrated the relationship between IL dose and FFAu concentrations in previous
publications [19]. When lipid emulsion is infused, the TG is hydrolyzed by lipoprotein
lipase via C-II in the endothelial surface to FFA which in turns is taken up by various organs
for metabolic fuel and to fat tissue to be re-esterified back to TG [20]. If the preterm infants
had low lipoprotein lipase (LPL) activity, the result will be a high TG but low FFAu levels.
We speculate that in our study subjects IL dose increase was accompanied by reduced
metabolic utilization of FFAu resulting in increased FFAu level. The latter could cause a
dissociation of C-II from LPL inhibiting the hydrolysis accounting for the elevation of TG. It
appears that the increased dose of IL may not achieve the desired increase in metabolic fuel
as expected.
It is of interest that the rate of IL infusion correlated with TG levels with a number of infants
manifesting TG above 250 mg/dL in spite of limiting the infusion rate below 0.15 g/kg/hour,
which was suggested to be a safe rate [1]. FFAu levels also increased, correlating with TG
levels, but there was no relationship with FFAu levels and TG when the latter exceeded 250
mg/dL.
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Our findings are consistent with the previous report of the sensitivity of infants below 29
weeks of gestation to manifesting elevated levels of TG due to IL infusion [21]. The elevated
FFAu and TG levels suggest a deficiency in the metabolism of IL and question the benefits
of intravenous fat infusion if the nutritional advantages are absent compared to the potential
risks.

Author Manuscript

Our results also demonstrated that FFAu levels in the preterm infants are not predictable and
often elevated. The potential toxicity of excessive FFAu levels in this population remains to
be elucidated. In adults, elevated levels of FFAu inhibit T lymphocyte signaling [22]. In a
previous investigation, we observed that in unstressed newborn rats, FFAu levels decreased
over the course of the first week of life, while levels in rats exposed to severe hypoxic
conditions were significantly elevated [23]. The elevated FFAu levels were thought to be due
to inflammatory mediator caused lipolysis. In another study, we showed that umbilical cord
FFAu levels were significantly higher in infants with lower Apgar scores with an inverse
correlation noted between umbilical cord FFAu levels and cord pH [24]. These findings were
thought to be due to increased serum catecholamine levels during the stressful period or,
alternately, reduced myocardial uptake of FFA during ischemia [25,26].
The unbound free fatty acid (FFAu) level in adults is 1.5 ± 0.9 nM and in term infants 13.9
± 3 nM. The high FFAu levels in preterm infants are like and even exceed those in adults
with a greatly increased risk of death highly correlated with elevated FFAu levels. In the
TIMI II trial of ST-elevation myocardial infarction, the median FFAu levels in the fourth
quartile of 1864 patients was 10 nM and these patients had a seven-fold greater risk of death
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relative to those in the first quartile (median 1.9 nM) [13]. Elevated levels of FFAu may not
only be associated with neonatal mortality [27] but with increased morbidity since albuminbound bilirubin is displaced by FFAu thus increasing the risk bilirubin related neurotoxicity
[28].
In conclusion, intralipid administration in large doses raises TG and FFAu levels in
premature infants and increases the risk of potential morbidity and mortality due to bilirubin
displacement. TG and FFAu levels are unpredictable and thus require monitoring during
intralipid administration. However, the utility of intralipid administration to provide calories
needs to be addressed in infants who demonstrate intolerance to the infusion.
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Figure 1.

Author Manuscript

The rate of intralipid administration and triglyceride levels. Figure 1 demonstrates rate of
Intralipid administration from 0.02 to 0.15 g/kg/hour and serum triglyceride levels from 20
to 450 mg/dL. (r = .24, p < .05).
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Figure 2.

Unbound free fatty acid levels (below 200 nM) and triglyceride levels. Figure 2 shows the
relationship between FFAu and triglyceride (TG) levels (r = .29, p < .05).
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3

0.126 ± 0.020

0.081 ± 0.009

0.053 ± 0.069

–

IL Rate of infusion, g/kg/hr

135.6 ± 118

140.2 ± 188

77.4 ± 50

72.6 ± 27

Triglyceride, mg/dL

.004

.04

a

p

98 ± 234

47.3 ± 102

17.7 ± 13

12.4 ± 4

FFAu, nM

p values document TG and FFAu levels at IL doses of 2 and 3 g/kg/24 hr compared to TG and FFAu levels at IL dose of 1 g/kg/24 hr.

a

40

2

5
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Samples (N)

0

Intralipid dose, g/kg/24 hr
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Triglyceride levels, rate of IL infusion, and FFAu at different IL doses.

.03

.07
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p
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TG and FFAu Levels with reference to gestational age.
IL dose g/kg/24 h

Triglyceride, mg/dL
<29 wks

≥29 wks

FFAu, nM
p

<29 wks

≥29 wks

p

0

57 ± 21 n= 3

97 ± 8 n= 2

.09

14.4 ± 3 n= 3

9.5 ± 3 n= 2

.18

1

97.1 ± 64 n= 19

61.1 ± 26 n= 23

.018

18.7 ± 14 n= 19

16.8 ± 11 n= 23

.63

2

227.9 ± 265 n= 17

75.3 ± 30 n= 23

.009

80.2 ± 152 n= 17

21.8 ± 11 n= 23

.07

3

160.6 ± 128 n= 19

118 ± 128 n= 27

.23

45.7 ± 109 n= 27

.07

172 ± 332 n= 19
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